N🟁N

Patient Home Monitoring begins trading on the TSX Venture Exchange

  //stocks-investing.news-articles.net/content/201 .. -begins-trading-on-the-tsx-venture-exchange.html
  Published in Stocks and Investing on Tuesday, June 8th 2010 at 4:10 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

SAN FRANCISCO, June 8 /CNW/ - Patient Home Monitoring (PHM) (TSXV:PHM), a company focused on in-home cardiology healthcare services, today announced that it will begin trading under the ticker symbol "PHM" on the TSX Venture Exchange at the open of market today, Tuesday, June 8, 2010.

"The PHM team is very happy to begin trading on the Toronto Venture Exchange," said Michael Dalsin, Chairman of Patient Home Monitoring. "It is an important step for the Company. We anticipate that this listing, along with the many relationships we have established in the market with both institutional and retail investors, will significantly add to the share value over time, as PHM realizes the financial benefits from penetrating the lucrative in-home US healthcare market."

PHM provides high quality in-home diagnostic services to cardiology patients. Importantly, PHM has a unique value proposition for physicians, creating a true partnership with their patients. PHM's centre of operations is its Patient Support Center (PSC) in San Francisco which provides the foundation for this partnership. Leveraging its PSC, PHM offers physicians a systematic approach to patient enrollment that results in costs savings and increased revenues for physician groups.

PHM will update the capital markets on its progress quarterly, and provide access to management through conference calls to discuss financial results, as well as through direct interaction with investors.

About PHM

PHM is a healthcare services company focused on providing in-home testing for patients on blood thinner medications such as Coumadin or warfarin. Medicare recently expanded reimbursement for in-home patient self testing (PST) of blood coagulation levels. PHM has a unique value proposition to cardiology groups that manage patients on blood thinners, focusing on systemization of enrolling patients in PST. This unique, systemized approach creates an opportunity for physician groups to operate more efficiently, while providing a higher standard of care for patients.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

%SEDAR: 00008298E